IGC Pharma Stock Surges 69.4% in After-Hours Trading on Positive Earnings and Drug Development Advances.

IGC Pharma's stock surged 69.4% in after-hours trading, following a presentation of a scientific poster at the 2025 Genetic Toxicology Association Annual Meeting and the company's beat of analyst estimates in its fourth-quarter earnings. IGC Pharma is involved in the development of cannabinoid-based therapies for Alzheimer's disease. The company's stock has been on a rollercoaster ride recently, with a drop to $0.32 on Tuesday and a rebound in after-hours trading.

IGC Pharma Inc. (IGC) experienced a significant surge in its stock value during after-hours trading on Wednesday, July 1, 2025. The stock price increased by 69.40%, closing at $0.62 after trading at $0.37 during the regular market session [1].

The stock's rebound comes after a tumultuous week. On Tuesday, IGC's stock value dropped to $0.32, but it has since rebounded, indicating strong investor confidence. The surge can be attributed to two key developments: the presentation of a scientific poster at the 2025 Genetic Toxicology Association Annual Meeting and the company's beat of analyst estimates in its fourth-quarter earnings [2].

At the annual meeting, IGC presented a scientific poster titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," showcasing its progress in Alzheimer's drug development. Additionally, the company reported an earnings per share of $(0.01) and sales of $330 million, beating the $305 million estimate [1].

IGC Pharma has been making significant strides in its field, focusing on cannabinoid-based therapies for Alzheimer's disease. The company's strategic partnership with a leading biotechnology firm, announced on July 10, 2025, is expected to accelerate the development of innovative therapeutic solutions [2].

The stock's performance is also influenced by the company's commitment to sustainability and corporate social responsibility. IGC has implemented several initiatives to reduce its environmental footprint and promote ethical business practices, resonating positively with investors [2].

IGC's stock has shown momentum, with Benzinga Pro Data indicating a 14.02% increase in the Wednesday market session and Benzinga Edge Stock Rankings placing the stock in the 20th percentile [1].

The company's recent developments, including the introduction of its proprietary AI-powered diagnostic platform, MINT-AD, designed to identify individuals at high risk of cognitive decline, have also contributed to its stock's performance [3].

References:

[1] https://www.benzinga.com/markets/equities/25/07/46335158/massive-69-4-surge-for-igc-pharma-in-after-hours-trading-heres-why
[2] https://www.ainvest.com/news/igc-pharma-stock-soars-57-92-partnership-sustainability-2507/
[3] https://www.nasdaq.com/press-release/igc-pharma-introduces-mint-ad-proprietary-ai-platform-predict-alzheimers-risk-and